IDEAYA Biosciences (FRA:30J) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences 3-Year Dividend Growth Rate?

IDEAYA Biosciences's Dividends per Share for the three months ended in Mar. 2025 was €0.00.

The historical rank and industry rank for IDEAYA Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:30J's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.95
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

IDEAYA Biosciences's Dividend Payout Ratio for the three months ended in Mar. 2025 was 0.00. As of today, IDEAYA Biosciences's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of IDEAYA Biosciences's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, IDEAYA Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's 3-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

IDEAYA Biosciences 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

IDEAYA Biosciences (FRA:30J) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

IDEAYA Biosciences's Dividend Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2025 )	/	EPS without NRI (Q: Mar. 2025 )
	=	0	/	-0.767
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEAYA Biosciences 3-Year Dividend Growth Rate Related Terms>

IDEAYA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

IDYA:USA

Address

5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Headlines

No Headlines